The main metabolic pathway of domperidone is through CYP3A4. In vitro data suggest that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone. In vivo interaction studies with ketoconazole revealed a marked inhibition of domperidone's CYP3A4 mediated first pass metabolism by ketoconazole. 4.6 Pregnancy and lactation and clemastine.
Intelligence and aptitude tests. On one of them I scored high enough to be tapped by the Army Security Agency. They wanted me. And the ASA had first choice. But the results of the tests were not given out until nearly the end of basic training, just before the bivouac. Apparently the barracks sergeant saw the results. Instead of being a physically hardened hardnosed private that would make a good platoon leader, I was just one of those egg-heads who were going to go into the the Army Security Agency. So all of a sudden, I was relieved of my responsibilities of being platoon leader. Then, on the first night of bivouac I caught guard duty. One night without sleep isn't so bad. I handled the next day's activities with no real problem. Then I was assigned guard duty again. It was supposedly a random thing. It was harder to stay awake this time, but I was in top shape. I could do it. And do it, I did. The third night, they selected guard duty a different way. And again, I had guard duty. That wasn't a coincidence. That morning we packed up our gear and started to march the 15 miles back to our barracks. I started out somewhere near the back of the main group. It was one of those hurry up and wait marches. Well, I was exhausted physically, mentally, and emotionally. I wasn't going to run to play catch up and then stand and wait. I walked a comfortable pace. Rather quickly there were two groups of men. Those in front and those who couldn't keep up who brought up the rear. I was marching to my own drummer somewhere between the two groups. With the Company Commander looking on from his jeep, my barracks sergeant ordered me to either join the first group or fall back with the second group. I told him to go to hell. He started toward me. I threatened to kill him. I raised my M-1 to an attack position. I used a few very typical army expletives and let him know very clearly that I wasn't going to let him continue "messing" with me. He backed off. I marched by myself between the two groups back to the barracks. I had fully expected to be called into the CO's office. I wasn't. I didn't say anything to the other men. And the other men didn't ask me any questions. Basic training was over. After a short leave I reported to Fort Devens to sit around waiting for my Top Secret Security Clearance to come through. Now, anybody who has been in the service will tell you never volunteer for anything. And they're right with one exception. Back then not many men could type and I knew the army ran on typewriters. Today, it's computers, but back then it was typewriters. At the very first morning roll call after arriving there, the sergeant asked if anyone could type. I volunteered. The next thing I knew I was working for the 1st Sergeant and making out the duty roster and typing out the weekend passes. Guess who never went on K.P. and who always had a weekend pass! All of us there had to wait until our clearances came through before we could go to an ASA school. I quickly found out what school I would be going to. It would be the Morse Code school. The thought of spending eight hours a day listening to and transcribing dit dot dits was not at all appealing to me. When I found out that the ASA was also looking for candidates for the Army Language School, I asked to take the test to see if I could qualify. Test taking had become a game to me. It was a game I was good at. I passed with flying colors. Now, I had to extend my tour of duty if I wanted to go there. I figured one more year would be worth it. I'm sure I was right. My Top Secret Security Clearance was slow in coming through. Of my group from Fort Leonard Wood, I was one of the last to get mine. That's why I so!
Groups. New groups planned at the Ukiah Resource Center site will include a easy movement dance class, a time for sharing music and poetry, and "Movin' On." Murphy explained that "Movin' On" is a mutual support group for people whose struggle has included a mix of drugs or alcohol challenges and emotional difficulties. AHC additionally offers groups for women and for men, a weekly support group and clopidogrel.
| Bank clinical diagnostic criteria bradykinesia and at least one of muscular rigidity, 4-6 hz rest tremor, or postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction ; .12 A convenience sample of 35 patients with `new-onset' parkinsonism not felt to be due to neuroleptic medication use or previously diagnosed idiopathic Parkinson's disease were studied further. To assess motor function, all sample patients completed 3 trials of the tap test `tap your hand as many times as possible in 15 seconds between 2 pie plates 20 cm apart' ; and 3 trials of Timed up and go TUG ; test `Stand, walk 3 metres, turn around, and come back, as quickly as is safely possible' ; . Patients then received 100 mg 25 mg of levodopa carbidopa and 10 mg domperidone to prevent levodopa-induced nausea and vomiting ; orally. Three trials each of the tap test and TUG test were repeated 1 hour after administration of levodopa carbidopa and domperidone. The mean of the 3 trials was taken at each stage; a positive levodopa response was defined as a 20% or greater improvement in either tap test or TUG test performance. Patients with a positive levodopa response were prescribed levodopa carbidopa 100 mg 25 mg twice daily with domperidone 10 mg twice daily, with dosage adjustment at the discretion of the attending physician. All patients with a positive levodopa response were reassessed for continued response at 1 week and 1 month after levodopa initiation. For all patients assessed, the diagnosis of dementia and dementia-type was made by the specialist in geriatric medicine providing ongoing care for the patient while in hospital on the geriatric inpatient unit. In most cases, results of a recent computerized tomography CT ; 61% ; or magnetic resonance image MRI ; 12% ; scan of the brain was available before discharge. All statistical analyses were performed with SPSS software version 9.0, SPSS, USA ; . The ability to predict `new-onset' parkinsonism was examined using multivariate analysis. RESULTS Of 1, 009 consecutive discharges, 51 were 65 years of age; discharge summaries were unavailable for 108 patients, leaving a sample of 850 patients. Of the patients, 42 5% ; were labelled as having parkinsonism by other physicians, but did not meet.
PPIs are more effective than H2RAs at reducing dyspeptic symptoms in trials of patients with uninvestigated dyspepsia. However individual patients may respond to H2RA therapy. In one trial of one year duration, patients receiving a PPI or a prokinetic experienced similar time free of symptoms. Cisapride is no longer licensed in the UK and evidence is sparse for Domperidone or Metoclopramide and cloxacillin!
Some medications are noted with N, QD, QL, or DS. The definitions for these symbols are listed below. Your benefit plan determines how these medications may be covered for you. Notification. There are a few medications that your doctor must notify us of to make sure their use is covered within your benefit. Quantity Duration. Some medications have a limited amount that can be covered for a specific period of time. Quantity Level. Some medications have a limited amount that can be covered at one time. Diabetic Supplies. Diabetic supplies may be covered by your benefit plan. Many benefit plans exclude coverage of medications that are classified by the Pharmacy and Therapeutics Committee as therapeutically equivalent to over-the-counter medications. Check your benefit plan documents for coverage information or call the Customer Care number on your ID card for more information. 100-7511 F1000 5 07 Advantage PDL!
|
Ii ; Hiccup: The causes of hiccup in a cancer patient are gastric distension, diaphragmatic irritation, phrenic nerve irritation, brain tumor, infection and rarely iatrogenic ie chemotherapy-induced. The treatment includes reducing gastric distension by antiflatulents, metoclopramide, domperidone and nasogastric intubation; pharyngeal stimulation; elevation of PCO2 by breath holding and rebreathing; central suppression of hiccup reflex by chlorpromazine; and suppression of central irritation from intracranial tension by phenytoin and sodium valproate 14 ; . iii ; Lymphoedema: The causes of lymphoedema include surgery and or radiotherapy to axilla or groin, postoperative infection and recurrent disease 15, 16 ; . The and cromolyn.
Domperidone is to be given only by o product rating: buy at: sundrugstore: 80 medstore: 00 - 6 from 2 store s ; imodium brand 2 mg product rating: buy at: world remedium: 16 world remedium: 86 world remedium: 00 - from 1 store s ; levbid 375mg 30 tablets levbid is used to control conditions such as excessive stomach acid production, excessive secretion from the pancreas, and excessive sweating and drooling associated with diseases like parkinson's disease.
Human SIRT1 enhances DNA repair capacity 1, 2 Jaemin Jeong , Hansoo Lee and Kee-Ho Lee 1 Korea Institute of Radiological and Medical Sciences and 2Kangwon National University Hybrid sensory kinase Slr1324 and Sll1229 regulate the gliding motility of Synechocystis sp. PCC 6803 Eunmi Lee, Young-Seon Jeon, Bong-Jeong Shin and Jong-Soon Choi Korea Basic Science Institute and danocrine.
Quinelorane were assessed by observing the behavioral responses of male rhesus monkeys to a sexually receptive female monkey that they could see, hear, and smell, but not physically contact. Quinelorane IM ; treatment produced dose-dependent effects on male sexual responding. Penile erections and masturbation were markedly facilitated following treatment with either 2.5 or 5 micrograms kg quinelorane. Higher doses of quinelorane 10 and 25 micrograms kg ; generally did not further augment sexual responding, but rather resulted in a return in sexual responding to control vehicle levels. Quinelorane had a biphasic effect on yawning behavior of the monkeys with low doses 2.5 and 5 micrograms kg ; facilitating yawning and high doses 25 micrograms kg ; inhibiting yawning. Quinelorane in the doserange 1-25 micrograms kg ; being evaluated did not reliably influence stereotypic behavior. In order to determine whether quinelorane acts centrally or peripherally to stimulate male sexual behavior, the ability of the peripherally active dopamine antagonist, domperidone, and the centrally active dopamine antagonist, haloperidol, to block the facilitation of sexual behavior produced by quinelorane treatment was examined. Administration of domperidone 50-200 micrograms kg ; failed to block quinelorane's effects on sexual behavior, whereas treatment with haloperidol 5-20 micrograms kg ; prevented quinelorane from stimulating male sexual responding. These experiments provide further evidence that dopaminergic mechanisms may play a role in the regulation of male sexual behavior of rhesus monkeys and, in particular, demonstrate the sexual stimulant properties of agents that provide central stimulation to D2 dopamine receptor sites. Pomerantz, S. M., B. C. Hepner, et al. 1993 ; . "5-HT1A and 5-HT1C 1D receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys." Eur J Pharmacol 243 3 ; : 227-34. Research has indicated that serotonin 5-HT ; is involved in regulating male sexual behavior in rodent, as well as primate species. The present study was designed to further characterize 5-HT influences on male sexual behavior of rhesus monkeys. Experiment 1 examined the effects of 5-HT1A and 5-HT1C 1D receptor stimulation on penile erections and yawning behavior. Administration of the 5-HT1C 1D receptor agonist, m-chlorophenylpiperazine mCPP, 0.8 and 3.0 mg kg ; , facilitated the occurrence of penile erection, and at doses greater than 0.2 mg kg stimulated yawning. By contrast, the 5-HT1A receptor agonist, 8-hydroxy-2 di-n-propylamino ; tetralin 8-OH-DPAT, 0.01-0.2 mg kg ; did not significantly influence penile erections or yawning behavior. Experiment 2 evaluated the effects of m-CPP and 8OH-DPAT on the behavior of male monkeys in the presence of a sexually receptive female monkey which the males could see, hear and smell, but not physically contact. Administration of m-CPP along with presentation of a receptive female stimulated penile erections to a greater extent than they were stimulated by either one of these manipulations alone. Administration of 8-OH-DPAT 0.1 and 0.2 mg kg ; produced a decrease in the percent of monkeys exhibiting penile erections in the presence of the female. In this experiment, yawning was affected in opposite directions, with m-CPP stimulating and 8-OH-DPAT decreasing the frequency of yawning. Experiment 3 assessed the effects of m-CPP on male copulatory behavior of rhesus monkeys. Administration of m-CPP 0.8-3.0 mg kg ; produced a dose-dependent decline in the percent of males initiating copulation and achieving ejaculation. ABSTRACT TRUNCATED AT 250 WORDS ; Poncelet, M., J. Souilhac, et al. 1994 ; . "Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats." Psychopharmacology Berl ; 116 2 ; : 237-41. One major mechanism underlying the central action of neurotensin is an interaction with the function of dopamine DA ; -containing neurons. In addition, direct or indirect DA agonists have been reported to promote neurotensin release. We have found that SR 48692, a nonpeptide neurotensin receptor antagonist 0.04-0.64 mg kg orally ; , antagonizes 50-65% ; yawning induced by apomorphine 0.07 mg kg SC ; or bromocriptine 2 mg kg IP ; in rats, and turning behaviour induced by intrastriatal injection of apomorphine 0.25 micrograms ; , + ; SKF 38393 0.1 micrograms ; , bromocriptine 0.01 ng ; or + ; amphetamine 10 micrograms ; in mice. Other apomorphine-induced effects in mice and rats such as climbing, hypothermia, hypo- and hyper-locomotion, penile erections and stereotypies were not significantly modified by SR 48692. Taken together, these data suggest that neurotensin may play a permissive role in the expression of some but not all behavioural responses to DA receptor stimulation. Postert, T., D. Pohlau, et al. 1996 ; . "Pathological yawning as a symptom of multiple sclerosis." J Neurol 243 3 ; : 3001. Potterton, D. 1984 ; . "From hospital to home, three. The yawning gap." Nurs Times 80 32 ; : 34-5. Protais, P., I. Dubuc, et al. 1983 ; . "Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats." Eur J Pharmacol 94 3-4 ; : 271-80. Increasing doses of apomorphine APO ; induced the dose-dependent appearance of yawns in rats at doses up to 0.1 mg X kg-1 and their disappearance from 0.1 to 0.6 mg X kg-1. A.
Buy cheap domperidone
Web sites supporting the drug's use are incorrect in touting the listing as an official endorsement of domperidone's safety, said dr and ddavp.
Join to post gamo 38 domperidone thu, april 12, 2007 - 5: 12 reglan works best with less side effects domperidone is not recommanded anymore!
Young-Won Chin1, Mark Bahar1, William J. Keller2, Karl A. Werbovetz1, and A. Douglas Kinghorn1 Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. 2Nature's Sunshine Products, Inc., 1655 N. Main St., Spanish Fork, UT 84660, USA and stimate and domperidone.
Precautions while using this medicine it isimportant that your doctor check your progress at regular visits to make surethe medicine is working properly.
640. 641. 642. Vat Olive OMW Victoria Blue-B0 Basic Blue 7 ; C.I. No. 42595 Victoria Blue-R Basic Blue-11 ; C.I. No.44040 ; Vat Yellow GCN U D Vat yellow 2 ; Fibreglass Insulation Product Glass Fibre Woven Roving Hand Cut Lead Crystal Glass ware High Density Alumina Ceramic Grinding Media Lead Glass Tube Procelain Mugs Decorated ; Fluoboric Acid Potassium Titanium Fluoride Sodium Hydrosulphite 3-Chloropropyl Trimethoxy silane 3-Mercapto Propyl Tri Methoxy Silane Activated Di-Methicone IP Diaminomatino Nitrite N- Cyclohexyl thio ; Phthalimide BIS Trimethyl Silyl ; Acetamide BIS Trimethyl Silyl ; Urea BSU ; Hexa methyl Disi lazane Hexa methyl Disiloxane Trimethyl Chloro silane Paraquet Groved Rubber pads Deleted Compatible Black Toner for photo copiers other than Xerox 1025 ; Cross linking Agent V-CL 300 ; CIS + Hydroxy Lactam. CIS + ; -2 4-Methoxy Phenyl ; -3Hydroxy-2, 3-Dihydro-1, 5-Benzothia-zepin-4- 5H ; - one 4-Bromo-2-Fluoro Biphenyl Astemizole Ciprofloxacin Hydrochloride Base Cisapride Monohydrate B.P Dextro Methorphan Hydrobromide Domperidone Domperidone Maleate Enalapril Maleate Enrofloxacin Famotidine Ketorolac Tromethamine N-Benzyl-4-Piperidone N-Carbethoxy-4-Piperidone N-Methyl-4-Piperidinol Norfloxacin Omeprazol Omeprazol Pellets Pefloxacin Methane Sulphonate Powder Pefloxacin ; High voltage porcelain insulators for transmission line applications of the following type: a ; Ball and Socket Disc Insulators b ; Antifog Disc Insulatorsc ; Pin Type Insulator d ; Tongue & Clevis type Disc Insulator. High Voltage Solid Core Porcelain Insulators High Voltage Tubular Porcelain Insulators Acetic Acid Glacial 3 4 and desmopressin.
6. The following note was added "only give haloperidol after patient has received at least 10 mg lorazepam." Intravenous levetiracetam Keppra ; - IV levetiracetam is a new IV formulation of the antiepileptic drug. - The injection and tablets are bioequivalent; therefore, the IV formulation will be added to formulary with automatic PO conversion after 24 hours if the patient is receiving other oral medications OR the patient has enteral access and is receiving other medications through the tube. Domperidone - Domperidone is an oral dopamine agonist widely used for over 10 years in Europe and Canada for the treatment of gastric disorders primarily gastroparesis ; . - The powder formulation is available in the United States, and many compounding pharmacies supply it to patients with a prescription. - The P&T Committee approved the following policy: 1. Domperidone will be nonformulary at MHMH; the Pharmacy will not acquire it for inpatient use 2. Patients may take their home medication if: - An informed consent is signed. - The physician writes an order that the patient can take his her home medication. - The medication is labeled in its original container prescription bottle. Urinary incontinence Medications Interchange - There are now 8 urinary incontinence medications available on the market. In order to decrease inventory, a therapeutic interchange was recommended. - Generic oxybutynin, generic tolterodine, and Detrol LA will be retained on formulary. All others will be interchanged to a formulary agent. Carbapenem Interchange - Imipenem will be the carbapenem of choice. - All orders for meropenem will be interchanged to imipenem. - Exclusions to the interchange include a documented seizure disorder, neurosurgery patient, meningitis, and an order written "DNS" do not substitute ; . Warfarin INR on Admission - The Department of Pharmacy has a new policy with patients admitted on warfarin. - When the physician has not ordered an INR on admission, the pharmacist will write an order for a "STAT" INR and will not dispense dose until the INR is back. - Once the INR is back, if supratherapeutic INR 3.5 ; , physician will be contacted for discontinuation of warfarin. - All subsequent INR monitoring will be the responsibility of the prescribing physician.
Thank you for visiting our cinnarizine-domperidone information page.
Drug Name Brands ASMANEX Drug Tier 2 Req. Limits!
From all the info i have read propulsid and domperidone are closely related chemicaly as well as in how they work.
How to buy cinarizina-domperidona online in the eu buying discount cinarizina-domperidona cinnarizine and domperidone ; online via prescription europe is simple and convenient and cisapride.
Every medical so have book is intake.
Tissue. Common sites of endometriosis include the cervix, the vaginal-rectal space, and ovary, fallopian tubes, colon and bladder wall. Common accompanying symptoms include dysmenorrhea, pathological uterine bleeding, and bleeding at sites other than the endometrium during menstruation. Some women bleed at sites as distant as the nasopharynx during menstruation and get nosebleeds during the menses. Endometriosis is classified as to its severity. Mild endometriosis - implants are small, flat patches of endometrial tissue growing outside of their normal location. Moderate endometriosis - includes "chocolate cysts" of endometriosis may be smaller than a pea or larger than a grapefruit, located within the ovary. Severe endometriosis - in some cases, bands of fibrous scar tissues adhesions ; bind the pelvic organs together. Interestingly enough, except for the obvious mechanical obstruction found in severe endometriosis, there seems to be no real correlation between the severity of endometriosis and its impact on fertility. However, as many as half of the women who have been diagnosed with infertility are found to have endometriosis on laparoscopic examination. Some women, in fact, have no symptoms at all, and diagnosis is only made through laparoscopy. Symptoms which may accompany endometriosis include abnormally heavy bleeding, associated with back pain or severe abdominal cramping, painful intercourse, painful intestinal upset or urination during the menstruation, and the inability to become pregnant. Western medical treatment usually includes pain relieving medication, laparoscopy and laser removal of the endometrial tissue. Other drugs may be used to control the hormonal stimulation of the endometriosis. As menstruation ceases each month, the misplaced endometrial tissue will be starved of hormonal stimulus, and thus mollify the endometriosis response. Of course, ovulation is also halted in this process, which defeats our present purpose.
Cheap domperidone
Obesity and diabetes The prevalence of diabetes has increased steadily over the past 20 years, and it has been accelerated by the epidemic of obesity in the United States.37-39 During the past year alone, 1.5 million new cases of diabetes were diagnosed in adults. 40 The prevalence of diabetes in children is also increasing rapidly.39, 40 The rising prevalence of diabetes will contribute to steady utilization growth for diabetes medications over the next few years. The prevalence of obesity and overweight in the United States has accelerated the development of diabetes in both adults and children. During the period 1999 to 2002, about 65% of adults between the ages of 20 and 74 were overweight, including 31% who were obese.41 Based on similar criteria, about 30% of children and adolescents between the ages of 6 and 19 are overweight, including 15% who are obese. 42 Tighter control A long-term clinical trial has recently demonstrated that tight control of blood glucose can reduce the macrovascular, as well as the microvascular, complications of diabetes. 43 Combinations of oral agents are being used more frequently to help patients reach aggressive hemoglobin A1C targets, such as the 6.5% level recommended by the American College of Endocrinology.44 Two- and three-drug combinations are frequently needed to help achieve adequate blood glucose control. Only about 7% of patients with diabetes achieve their target goals for blood glucose, cholesterol, and blood pressure.45 The remaining patients represent an undertreated population that may drive future utilization growth for diabetes medications, including oral hypoglycemic agents, insulin products, and drugs that help manage the complications of diabetes. Inhaled insulin The first inhaled insulin product, Exubera, received FDA approval in January 2006. One or two additional inhaled insulin products may come to market in the next few years. In patients with type 2 diabetes, inhaled insulin will generally be used in combination with oral agents to achieve more tightly controlled postprandial blood glucose. Some concerns about potential long-term pulmonary toxicity associated with Exubera remain unanswered. However, the changes in pulmonary function that have been reported with this product appear to be small and reversible. For nonsmoking patients who do not have a history of asthma or other respiratory conditions, this safety consideration is unlikely to significantly limit the acceptance of inhaled insulin products. New injectables Two new injectable treatments for diabetes were introduced in 2005--Byetta exenatide ; and Symlin pramlintide ; . Byetta, a glucagon-like peptide-1 agonist, has multiple effects on blood glucose control--it stimulates the secretion of insulin in the presence of elevated blood glucose, it slows gastric emptying to delay entry of ingested sugar into the bloodstream, and it inhibits secretion of glucagon. Over time, the use of Byetta may lead to weight loss--an atypical side effect among the drugs used to treat diabetes. This new injectable is likely to have a significant impact on utilization and cost in the diabetes category. Concerns about the potential hypoglycemic effects of Symlin appear to have limited its utilization to date. These injectable agents are likely to be used in combination with existing therapies, which will accelerate utilization growth for diabetes medications. A third injectable agent, liraglutide, is currently in development and may be introduced in 2008. Liraglutide acts similarly to exenatide, but is administered only once daily. A once-weekly dosage form of exenatide is also in clinical development and could reach the market by 2008. New oral agents Ruboxistaurin, a protein kinase C inhibitor, is in development for the treatment of diabetes complications, including diabetic retinopathy, diabetic macular edema, and diabetic peripheral neuropathy. In Phase III trials, this drug has demonstrated a significant reduction in sustained moderate vision loss in patients with diabetic retinopathy. Ruboxistaurin will be an.
209 hospitalists in MA 186 internists 23 pediatricians ; . They represent 173 FTEs Almost half of all MA hospitals have hospitalist programs some developed by hospitals and others developed by medical groups ; Hospitalists care for approx 42% of the state's 1.8 million medical inpatient days.
5. Barter RH, Dusbabek JA, Riva HL, Parks J. Surgical closure of the incompetent cervix during pregnancy. J Obstet Gynecol 1958; 75: 51124. Level III ; 6. Toaff R, Toaff ME, Ballas S, Ophir A. Cervical incompetence: diagnostic and therapeutic aspects. Isr J Med Sci 1977; 13: 3949. Level II-2 ; 7. Phung Thi Tho, Byrd JR, McDonough PG. Etiologies and subsequent reproductive performance of 100 couples with recurrent abortion. Fertil Steril 1979; 32: 38995. Level III ; 8. Harger JH, Archer DF, Marchese SG, Muracca-Clemens M, Garver KL. Etiology of recurrent pregnancy losses and outcome of subsequent pregnancies. Obstet Gynecol 1983; 62: 57481. Level II-2 ; 9. Harger JH. Cervical cerclage: patient selection, morbidity, and success rates. Clin Perinatol 1983; 10: 32141. Level III ; 10. Drakeley AJ, Roberts D, Alfirevic Z. Cervical stitch cerclage ; for preventing pregnancy loss in women Cochrane Review ; . In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software. Meta-analysis ; 11. Iams JD, Johnson FF, Sonek J, Sachs L, Gebauer C, Samuels P. Cervical competence as a continuum: a study of ultrasonographic cervical length and obstetric performance. J Obstet Gynecol 1995; 172: 1097103; discussion 11046. Level II-2 ; 12. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996; 334: 56772. Level II-2 ; 13. Shellhaas CS, Iams JD. Ambulatory management of preterm labor. Clin Obstet Gynecol 1998; 41: 491502. Level I ; 14. Rubovits FE, Cooperman NR, Lash AF. Habitual abortion: a radiographic technique to demonstrate the incompetent internal os of the cervix. J Obstet Gynecol 1953; 66: 26980. Level III ; 15. Kiwi R, Neuman MR, Merkatz IR, Selim MA, Lysikiewicz A. Determination of the elastic properties of the cervix. Obstet Gynecol 1988; 71: 56874. Level III ; 16. Anthony GS, Calder AA, MacNaughton MC. Cervical resistance in patients with previous spontaneous midtrimester abortion. Br J Obstet Gynaecol 1982; 89: 10469. Level II-2 ; 17. Andersen HF. Transvaginal and transabdominal ultrasonography of the uterine cervix during pregnancy. J Clin Ultrasound 1991; 19: 7783. Level II-3 ; 18. Kushnir O, Vigil DA, Izquierdo L, Schiff M, Curet LB. Vaginal ultrasonographic assessment of cervical length changes during normal pregnancy. J Obstet Gynecol 1990; 162: 9913. Level II-3 ; 19. Okitsu O, Mimura T, Nakayama T, Aono T. Early prediction of preterm delivery by transvaginal ultrasonography. Ultrasound Obstet Gynecol 1992; 2: 4029. Level II-2.
Part Three In Competition Testing 14 14.1 14.2 Selection of Matches Drug testing may be conducted at any match involving Participants and no prior notice needs to be given either to the Clubs concerned or to the Players. The matches at which the drug tests are to be conducted will be decided by The FA in consultation with UK Sport. All matches are open to testing. Procedures following the selection of Players Following the draw for In Competition testing the Club must allow the Competent Officials access to observe the Players from the tunnel area and or from an adjacent or nearby area of the pitch or stand where the Competent Officials can easily accompany the selected Players can be accompanied from the field of play by a Competent Official in the event of substitution, injury or other reason for leaving the field of play.
2. 3. 4. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. Br Med. J 1989; 298: 30-32. Tylgat GN. Patients with dyspepsia: A heterogeneous population. In: R.C. Heading and J.D. Wood eds. ; , Gastrointestinal Dysmotility: Focus on Cisapride, Raven Press. Ltd. New York 1992; pp201-211. Colin-Jones DG, BloomB, Bodemar G, etai Managementofdyspepsia: reportof a working party. Lancet 1988; I: 576-579. Waldron B. Cullen PT, Kumar R, el at. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multi-factorial study. Gut 1991; 32: 246-251. Talley NJ, Shutter B, McCrudden G, Jones M, Hoschi R, Piper DW. Lack of association between gastric emptying of solids and symptoms in nonulcer dyspepsia. J Clin. Gastroenterol. 1989; 11: 625-630. Talley NJ. Functional dyspepsia - Should treatment be targeted on disturbed physilogy? Aliment. Pharmacol. Ther. I995; 9: 107-115. BradetteM. ParcP, DouvilleP, Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distensions with placebo and domperidone. Dig. Dis. Sci. 1991; 36: 52-58 Mearin F, Cucala M, Azpiroz F. Malagelada JR. The origin of symptoms on the brain-gutaxis in functional dyspepsia. Gastroenterol. 1991; 101: 999-1006. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia Gastroenterol. 1994; 107: 271-293. Bechi P, Dei R, Amorosi A, Marcuzzo G, Cortesini C. Helicobacter pylori and luminal gastric pH. Relationships in nonulcer dyspepsia. Dig Dis Sci. 1992; 37: 378-384. Tucci A. Corinaldesi R, Stanghelleni V, et al. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gatroenterol, 1992, 103: 768-774. Bates S, Sjoden PO, Fellenius J, Nyren O. Blocked and nonblocked acid secretion and reported pain in ulcer, non-ulcer dyspepsia and normal subjects. Gatroenterol. 1989; 97: 376-383. George AA, Tsuchiyose M, DooleyCP. Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulcer dyspepsia. Gastroenterol. 1991; 101: 3-6. Marshall BJ, Warren JR. Unidentified curved bacillin in the stormach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315. Rokkas T Pursey C, Uzoechina E, Dorrington L, Simmons NA, Filipe MI, sladen GE. Campylobacter pylori and non-ulcer dyspepsia. Am. J. Gastroenterol. 1987; 82: 1149-1152. Rathbone BJ, Wyatt J. Heatley RV. Symptomatology in C. pylori-positive and negative non-ulcer dyspepsia. Gut 1988; 29: A 1473. Andersen LP, Elsborg L, Justesen T. Campylobacler pylori in peptic ulcer disease. III. Symptoms and paraclinical and epidemiologic findings. Scand. J. Gastroenterol. 1988; 23: 347-350. Borsch G, Schmidt G, Wegener M, el al. Campylobacter pylori: Prospective analysis of clinical and histological factors associated with colonization of the upper gastrointestinal tract. Eur. J. Clin. Invest. 1988, 18: 133-138. Loffeld RJLF, Potters HVPJ, Arends JW, Stobberingh E, Flendrig JA, VanSpreeuwel JP. Campylobacter associated gastritis in patients with non-ulcer dyspepsia. J. Clin. Pathol. 1988; 41: 85-88. Pettross CW, Appleman MD, Cohen H, Valenzuela IE, Chandrasoma P, Laine LA. Prevalence of Campylobacler pylori and association with antral mucosal histology in subjects with and without upper gastrointesinal symptoms. Dig. Dis Sci. 1988; 33: 649-653. Lambert JR, Dunn K, Borromeo M, Korman MG, Hansky J Campylobacler pylori - a role in non-ulcer dyspepsia? Scand. J. Gastroenterol. 1989; 24 suppl. 160 ; : 7-13 Deltenre M, NystJF, Jonas C, et a . Clinical, endoscopic and histolgic findings in 1, 100 patients of whom 574 were colonized by Campylobacter pylori. Gastroenterol Clin. Biol 1989; 13: 89B-95B. Sobala GM, Dixon MF, Axon ATR Symptomatology of Helicobacter pylori associated dyspepsia. Eur. J. Gastroenterol. Hepatol. 1990; 2: 445-449. Stauss RM, Wang TC, Kelsey PB, a al. Association of Helicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am. J. Med. 1990; 89: 464-469.
Source: Table 15.3.2, Section 13.
|
